Gilead Sciences company profile
Company profile
Gilead Sciences has 17,000 employees and is headquartered in Foster City, United States.
Based in Foster City, California, Gilead Sciences was incorporated in 1987 and works as a biopharmaceutical company that discovers, develops and commercializes medicines for areas of unmet medical need. Its HIV portfolio includes Biktarvy, Descovy and Genvoya, and it also offers the hepatitis treatments Epclusa and Vemlidy, the antifungal AmBisome and the COVID-19 treatment Veklury. In cancer and cell therapy it markets Yescarta, Tecartus and Trodelvy, and it develops immunotherapies for cancer and other serious diseases. Its products are sold in the United States, Europe and other international markets, and its collaborations include agreements with Merck Sharp & Dohme, Japan Tobacco, Arcus Biosciences and LEO Pharma, as well as a partnership with the Pan American Health Organization on lenacapavir for HIV prevention.
In the fiscal year ended December 2025, revenue reached 29.4 billion US dollars, up 2.4% from the previous year, and net profit was 8.5 billion US dollars. The United States accounted for 70.9% of revenue, Europe for 17.2% and the rest of the world for 11.9%. The company employs 17,000 people and is headquartered in Foster City.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- 333 Lakeside Drive, 94404, Foster City
- Employees
- 17,000
- Chief executive
- Daniel Patrick O'Day
- Founded
- 1987
- Fiscal year
- January - December
- Listing
- GILD · NASDAQ
- Indices
- Nasdaq 100S&P 500
- Currency
- USD
- ISIN
- US3755581036
- Website
- gilead.com
Gilead Sciences and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Gilead SciencesGILD | United States | $208.48B | 17,000 | 38.2% | — |
| AmgenAMGN | United States | $251.89B | 31,500 | 34.1% | 27.0 |
| PfizerPFE | United States | $164.67B | 75,000 | 29.1% | 41.3 |
| Bristol-Myers SquibbBMY | United States | $129.66B | 32,500 | 32.4% | 14.1 |
| Merck & Co.MRK | United States | $364.26B | 73,000 | 35.2% | 147.8 |
| AbbVieABBV | United States | $521.5B | 57,000 | 36.6% | 50.6 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
